Literature DB >> 15224357

NK-cell related neoplasms in Osaka, Japan.

Hajime Miyazato1, Shin-ichi Nakatsuka, Zhiming Dong, Tetsuya Takakuwa, Kazumasa Oka, Hitoshi Hanamoto, Yoichi Tatsumi, Akihisa Kanamaru, Katsuyuki Aozasa.   

Abstract

The frequency of NK-cell related neoplasms was estimated among lymphoproliferative diseases diagnosed and treated in Osaka, Japan, from 1999 to 2003. The total number of registered cases was 1,400, among which 1,092 patients were diagnosed as having malignant lymphomas. There were 987 cases of non-Hodgkin's lymphoma (NHL) and 105 (9.6%) of Hodgkin's lymphoma. Immunophenotypic analysis revealed that 743 patients had B-cell lymphomas and 209 T/NK-cell lymphomas. Among the T/NK-cell lymphomas, 40 showed positive immunoreactivity for CD56, and thus they were judged to be NK/T-cell lymphomas. They included one blastic NK-cell lymphoma and 39 NK/T-cell lymphomas. NK/T-cell lymphomas were further divided into three categories based on the main site of lesions: nasal type (23 cases), non-nasal extranodal type (11 cases), and nodal type (5 cases). The positive rate of infection with the Epstein-Barr virus determined by in situ hybridization was 83%, 36%, and 25% in the nasal, non-nasal, and nodal type, respectively. A mosquito allergy was found in one patient with EBV-positive non-nasal NK/T-cell lymphoma. The present study showed that the frequency of NK-cell related neoplasms among all NHLs was 4% in an ATL-non-endemic area of Japan. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224357     DOI: 10.1002/ajh.20091

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  1 in total

1.  Annular Erythematous Patches as the Presenting Sign of Extranodal Natural Killer/T-Cell Lymphoma.

Authors:  Can Baykal; Algün Polat Ekinci; Şule Öztürk Sarı; Zeynep Topkarcı; Özgür Demir; Nesimi Büyükbabani
Journal:  Turk J Haematol       Date:  2016-07-15       Impact factor: 1.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.